

DRAFT Minutes—Indiana Medicaid DUR Board
Meeting of January 16, 2009—Meeting No. 145

In attendance:

Brian Musial, R.Ph.--Chair
John Wernert, M.D.--Vice-Chair
Patricia Treadwell, M.D.
Terry D. Lindstrom, Ph.D.
Philip Eskew, Jr., M.D.
Kent Summers, R.Ph., Ph.D.
Jeff Brown, R.Ph., MS, BCPS

Also present:

Marc Shirley, R.Ph.--OMPP
Medina Lee, R.Ph.--OMPP
Kristin Johnson -- OMPP
Jeannine M. Murray, R.Ph.--Anthem
Chris Johnson, R.Ph.--MDwise
Randall Renshaw, PharmD, BCPS--ACS

MEETING CALLED TO ORDER: Mr. Brian Musial called the meeting of the Indiana Medicaid DUR Board to order.

APPROVAL OF MINUTES: Dr. Philip Eskew requested the meeting number be added to the meeting minutes. Mr. Marc Shirley requested Dr. Renshaw research the history of the numeric order of the meeting minutes and add this number to the January 2009 meeting minutes. Mr. Shirley also asked Dr. Renshaw to carry this sequential numbering forward for future meeting minutes. Dr. Eskew asked for approval of the minutes from the December meeting. His request was moved, seconded, and carried with a unanimous vote.

REMARKS FROM THE CHAIR: Mr. Musial thanked everyone for braving the minus 12 degree weather to attend the inaugural 2009 DUR Board meeting. Mr. Musial also thanked Dr. Patricia Treadwell, M.D. for the fabulous job serving as Board chair last year.

OPENING COMMENTS: Mr. Shirley also thanked everyone for attending the Board meeting under tough travel conditions. He stated that a memo from FSSA Secretary E. Mitchell Roob, Jr., dated December 11, 2009, instructed Dr. Jeffery M. Wells, Director, Office of Medicaid Policy and Planning (OMPP), to proceed with the Managed Care Organization (MCO) pharmaceutical carve-out project, to be effective July 1, 2009. Mr. Shirley added that in response to the carve-out announcement at the December 2009 DUR Board meeting, the Board had requested a copy of the MCO carve-out memo and a brief overview. Mr. Shirley said that an e-mail had been sent to the Board members containing a copy of the carve-out memo and a brief summary of the status of the carve-out. Mr. Shirley added that if there were any questions about the MCO carve-out, he or Mike Sharp would be glad to entertain them.

ACS UPDATE: Dr. Renshaw presented the prior authorization (PA) statistics for the month of December 2008. There were 3,928 approvals and 94 denials, totaling 4,022 transactions. Dr. Eskew asked why the proton pump inhibitors (PPIs) deny noting that these drugs deny more than any other agents. Dr. Renshaw stated that a patient must have a trial of omeprazole or Prilosec OTC within the past 90 days and then have a trial of a preferred PPI for a period of 4 weeks before receiving a non-preferred PPI. Dr. Eskew stated that a PPI intervention letter might be good for providers. Dr. Renshaw pointed out that a gastrointestinal retro-DUR intervention letter is being finalized and will be presented at the February Board meeting.

EFFECT OF IMPLEMENTING A PA REQUIREMENT FOR DRUG-DRUG SEVERITY LEVEL ONE INTERACTIONS: Dr. Renshaw stated the Board had previously requested that ACS summarize the general effect of implementing a PA requirement for drug-drug severity level one interactions. He added that

ACS examined pharmacist pro-DUR override rates prior to the January 15, 2003 implementation of the PA requirement, and noted that pharmacists overrode the alerts 84% of the time. Dr. Renshaw stated that ACS then examined the override rate after the PA requirement was implemented, and found that it resulted in a 33% override rate. He summarized by stating that requiring PA for drug-drug severity level one interactions resulted in a 51% reduction in overrides.

RETRO-DUR PROPOSALS: Dr. Renshaw presented two retro-DUR proposals. He stated that the topic of one of the proposals was hypertension, while the topic of the other was metabolic syndrome. Dr. Eskew commented that both of the proposals were very well done and that this is the type of thing the Board should be doing. It was moved and seconded that these two retro-DUR proposals be approved. The motion passed unanimously.

UTILIZATION EDITS RECOMMENDED BY THE MENTAL HEALTH QUALITY ASSURANCE

COMMITTEE: Dr. Renshaw asked if he could present the utilization edits recommended by the Mental Health Quality Assurance Committee (MHQAC). Mr. Musial said to please proceed. Dr. Renshaw stated the MHQAC met yesterday and recommended the following utilization edits: dextroamphetamine sulfate 5mg/5ml solution – 40ml per day, Dexedrine Spansule 5mg capsule – 2 capsules per day, Dexedrine Spansule 15mg capsule – 2 capsules per day, and Pexeva 40mg tablets – 1 tablet per day. Dr. Kent Summers questioned the indication for dextroamphetamine solution. Dr. Renshaw responded that the indications for dextroamphetamine solution are Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD). There was much discussion by the Board members regarding what they were being asked to approve. Dr. Renshaw pointed out the utilization edits were essentially quantity limits and that there are similar edits on other mental health medications. Dr. Renshaw went on to say that these quantity limits were researched and presented to the MHQAC. He also stated that the MHQAC voted and approved the utilization edits which are being presented to the DUR Board for approval. It was moved and seconded that the proposed utilization edits be approved. The motion carried with one opposition. Mr. Musial asked Dr. Renshaw if he could put these approved utilization edits in writing and send them to the Board members, and Dr. Renshaw agreed to do so. Dr. Wernert commented that he had attended the MHQAC meeting yesterday and indicated there was a lot of good data presented at the meeting that the DUR Board might be interested in. It was asked when the draft minutes of the MHQAC meeting would be available. Mr. Shirley responded that that MHQAC/Board secretary Karen Clifton was responsible for the MHQAC draft meeting minutes and that the draft minutes would be posted on the MHQAC's web site location. He said that he would send an e-mail alerting Board members when the MHQAC minutes were available for viewing. Mr. Shirley pointed out that the website for the MHQAC can be found at indianamedicaid.com, and further noted that minutes from previous meetings, agendas for future meetings, and documents having to do with utilization edits could be found at that location. He said that OMPP staff would be glad to answer any questions about information on the web site. Dr. Wernert pointed out the MHQAC would be discontinued this summer unless the legislature takes action for the MHQAC to continue. Dr. Wernert stated the MHQAC does important work and that he felt the MHQAC should continue. Mr. Shirley added that he understood there was a bill before the legislature to continue the MHQAC. It was moved and seconded that the DUR Board supports the continuation of the MHQAC. The motion passed unanimously.

MANAGED CARE ORGANIZATION UPDATE:

- Proposed PDL Changes—MDwise: Mr. Chris Johnson stated that he did not have any updates for the Board.
- Proposed PDL Changes—Anthem: Ms. Jeannine Murray stated that she did not have any updates for the Board.

NEW DRUGS: None.

LIAISONS WITH OTHER BOARDS: Mr. Musial stated that the Board of Pharmacy liaison had relocated and would no longer be able to function in this role. Mr. Musial asked for nominations for the position. There were no nominations. Dr. Eskew suggested that selection of the successor to the position should await appointment of new DUR Board members. Mr. Musial stated that he was going to continue to function as liaison to the Therapeutics Committee.

PUBLIC COMMENT: None.

OLD BUSINESS: None.

NEW BUSINESS: None.

MEETING ADJOURNED.